Loading clinical trials...
Loading clinical trials...
An Open Label, Positron Emission Tomography (PET) Study With [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
The purpose of this study is to determine the central 5-HT1B receptor occupancy of ZOMIG® Rapimelt (zolmitriptan) in healthy male volunteers.
Age
20 - 45 years
Sex
MALE
Healthy Volunteers
Yes
Research Site
Uppsala, Sweden
Start Date
May 1, 2010
Primary Completion Date
October 1, 2010
Completion Date
October 1, 2010
Last Updated
November 3, 2010
10
ACTUAL participants
Rapimelt
DRUG
[11C]AZ10419369
DRUG
Lead Sponsor
AstraZeneca
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions